CN117999265A - 取代的融合双环大环化合物及其相关治疗方法 - Google Patents

取代的融合双环大环化合物及其相关治疗方法 Download PDF

Info

Publication number
CN117999265A
CN117999265A CN202280047653.8A CN202280047653A CN117999265A CN 117999265 A CN117999265 A CN 117999265A CN 202280047653 A CN202280047653 A CN 202280047653A CN 117999265 A CN117999265 A CN 117999265A
Authority
CN
China
Prior art keywords
formula
another embodiment
alkyl
alkylene
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280047653.8A
Other languages
English (en)
Chinese (zh)
Inventor
黄霍安
L·D·彭宁顿
崔永吉
B·M·阿奎拉
I·A·马格
胡元
J·R·伍兹
B·K·雷默
J·M·本齐恩
J·W·莱曼
M·R·哈尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alkermes Inc
Original Assignee
Alkermes Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkermes Inc filed Critical Alkermes Inc
Publication of CN117999265A publication Critical patent/CN117999265A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202280047653.8A 2021-05-26 2022-05-25 取代的融合双环大环化合物及其相关治疗方法 Pending CN117999265A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163193243P 2021-05-26 2021-05-26
US63/193,243 2021-05-26
PCT/US2022/030839 WO2022251302A1 (en) 2021-05-26 2022-05-25 Substituted fused bicyclic macrocyclic compounds and related methods of treatment

Publications (1)

Publication Number Publication Date
CN117999265A true CN117999265A (zh) 2024-05-07

Family

ID=82851881

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280047653.8A Pending CN117999265A (zh) 2021-05-26 2022-05-25 取代的融合双环大环化合物及其相关治疗方法

Country Status (7)

Country Link
US (1) US20240182491A1 (https=)
EP (1) EP4347046A1 (https=)
JP (1) JP2024520395A (https=)
CN (1) CN117999265A (https=)
AU (1) AU2022281345A1 (https=)
CA (1) CA3219506A1 (https=)
WO (1) WO2022251302A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026017128A1 (zh) * 2024-07-17 2026-01-22 江苏恩华药业股份有限公司 作为食欲素受体激动剂的环烯烃衍生物及其组合物和用途

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250155550A (ko) 2023-03-16 2025-10-30 다케다 야쿠힌 고교 가부시키가이샤 매크로시클릭 헤테로시클 화합물 및 이의 용도
US20240425521A1 (en) 2023-06-01 2024-12-26 H. Lundbeck A/S Spiromacrocyclic orexin 2 receptor agonists
WO2025124698A1 (en) 2023-12-12 2025-06-19 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators
TW202542165A (zh) 2023-12-19 2025-11-01 瑞士商愛杜西亞製藥有限公司 大環食慾素激動劑
WO2026064378A1 (en) * 2024-09-18 2026-03-26 Vertex Pharmaceuticals Incorporated Macrocyclic sulfonamide modulators

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017135306A1 (en) * 2016-02-04 2017-08-10 Takeda Pharmaceutical Company Limited Substituted piperidine compound and use thereof
WO2018053302A1 (en) * 2016-09-19 2018-03-22 Ensemble Therapeutics Corporation Macrocyclic compounds for the inhibition of indoleamine-2,3-dioxygenase activity and use thereof
CN110088099A (zh) * 2016-12-19 2019-08-02 Epizyme股份有限公司 作为ehmt2抑制剂的胺取代的杂环化合物及其使用方法
CN110156813A (zh) * 2018-02-13 2019-08-23 北京诺诚健华医药科技有限公司 作为trk抑制剂的杂环化合物
CN110627812A (zh) * 2018-06-25 2019-12-31 北京诺诚健华医药科技有限公司 作为trk抑制剂的杂环化合物
EP3663281A1 (en) * 2017-08-03 2020-06-10 Takeda Pharmaceutical Company Limited Heterocyclic compound and application thereof
WO2020167706A1 (en) * 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
EP3816154A1 (en) * 2018-06-29 2021-05-05 Takeda Pharmaceutical Company Limited Heterocyclic compound and application thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8258163B2 (en) 2008-06-04 2012-09-04 Board Of Regents, The University Of Texas System Small-molecule agonists for type-2 orexin receptor
WO2014198880A1 (en) 2013-06-14 2014-12-18 Ferrer Internacional, S.A. 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity
US20160250224A1 (en) 2013-09-24 2016-09-01 The Board Of Regents Of The University Of Texas System Orexin-control of bone formation and loss
CA2930693A1 (en) 2013-11-15 2015-05-21 The Board Of Trustees Of The Leland Stanford Junior Unversity Methods of treating heart failure with agonists of hypocretin receptor 2
PE20161064A1 (es) 2013-12-12 2016-10-28 Univ Tsukuba Derivado de sulfonamida o sales de adicion de acido farmaceuticamente aceptables del mismo
WO2015147240A1 (ja) 2014-03-28 2015-10-01 国立大学法人筑波大学 敗血症の予防治療剤
US20200207734A1 (en) 2017-08-03 2020-07-02 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
FI4065585T3 (fi) * 2019-11-25 2025-09-26 Alkermes Inc Substituoituja makrosyklisiä yhdisteitä ja niihin liittyviä hoitomenetelmiä
WO2022109117A1 (en) * 2020-11-23 2022-05-27 Merck Sharp & Dohme Corp. 3-amino pyrrolidine and piperidine macrocyclic orexin receptor agonists
US12006330B2 (en) * 2020-12-21 2024-06-11 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017135306A1 (en) * 2016-02-04 2017-08-10 Takeda Pharmaceutical Company Limited Substituted piperidine compound and use thereof
WO2018053302A1 (en) * 2016-09-19 2018-03-22 Ensemble Therapeutics Corporation Macrocyclic compounds for the inhibition of indoleamine-2,3-dioxygenase activity and use thereof
CN110088099A (zh) * 2016-12-19 2019-08-02 Epizyme股份有限公司 作为ehmt2抑制剂的胺取代的杂环化合物及其使用方法
EP3663281A1 (en) * 2017-08-03 2020-06-10 Takeda Pharmaceutical Company Limited Heterocyclic compound and application thereof
CN110156813A (zh) * 2018-02-13 2019-08-23 北京诺诚健华医药科技有限公司 作为trk抑制剂的杂环化合物
CN110627812A (zh) * 2018-06-25 2019-12-31 北京诺诚健华医药科技有限公司 作为trk抑制剂的杂环化合物
EP3816154A1 (en) * 2018-06-29 2021-05-05 Takeda Pharmaceutical Company Limited Heterocyclic compound and application thereof
WO2020167706A1 (en) * 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026017128A1 (zh) * 2024-07-17 2026-01-22 江苏恩华药业股份有限公司 作为食欲素受体激动剂的环烯烃衍生物及其组合物和用途

Also Published As

Publication number Publication date
US20240182491A1 (en) 2024-06-06
AU2022281345A1 (en) 2023-11-30
WO2022251302A1 (en) 2022-12-01
JP2024520395A (ja) 2024-05-24
CA3219506A1 (en) 2022-12-01
EP4347046A1 (en) 2024-04-10

Similar Documents

Publication Publication Date Title
CN117999265A (zh) 取代的融合双环大环化合物及其相关治疗方法
KR102073797B1 (ko) 단백질 키나제 저해제로서의 아미노피리다지논 화합물
CN117440955A (zh) 具有食欲素-2受体激动剂活性的取代的酰胺大环化合物
CN107074852B (zh) ROR-γ的二氢吡咯并吡啶抑制剂
CN114286818B (zh) 作为bet抑制剂的杂环化合物
JP7846113B2 (ja) 置換ピペリジノ化合物及び関連する治療方法
US8889702B2 (en) Derivatives of azaspiranyl-alkylcarbamates of 5-member heterocyclic compounds, preparation thereof and therapeutic use thereof
JP2024501641A (ja) 置換大環状化合物及び関連する治療方法
CN102574860A (zh) 吡咯并[2,3-d]嘧啶化合物
KR20140040774A (ko) 이미다조피리딘 화합물
BG65925B1 (bg) Заместени пиролопиридинонови производни полезни като инхибитори на фосфодиестераза
KR20010094731A (ko) 이미다졸 화합물 및 그의 의약 용도
CN117651703A (zh) 取代的氨基甲酸大环化合物及其相关治疗方法
JP2023513373A (ja) Ｐ２ｘ３修飾薬
RU2162470C2 (ru) 2,7-замещенные производные октагидропирроло[1,2-а]пиразина, способ лечения, фармацевтическая композиция, промежуточные соединения
KR20000005505A (ko) 피페리딘 및 피롤리딘
CN119730843A (zh) 取代的吡咯烷基和哌啶基化合物以及相关的治疗方法
CN119768169A (zh) 取代的稠合二环化合物以及相关的治疗方法
CN119730848A (zh) 取代的吡咯烷基和哌啶基化合物以及相关的治疗方法
WO2016115013A1 (en) Cinnoline derivatives useful as cb-1 receptor inverse agonists
HK1172621A (en) Pyrrolo[2,3-d] pyrimidine compounds

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination